08 Jan 2021
Conference call on Report on Operations
Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the report on operations 2020. The presentation will be held in English.
Read moreNews Tag: Corporate Information
08 Jan 2021
Telefonkonferens avseende bokslutskommuniké
XVIVO Perfusion inbjuder till telefonkonferens med anledning av bokslutskommuniké 2020. Presentationen kommer att hållas på engelska.
Read more 01 Dec 2020
First patient in the European Heart Preservation study transplanted
The first patient in XVIVOs European Heart preservation study was transplanted during the month of November. The patent protected Heart Preservation device, developed by Professor Stig Steen and commercialized by XVIVO, uses a novel technique for preservation of the donor heart during transport. Nine European transplant centers will include a total of 202 patients in the trial that forms the basis of a European regulatory approval application and will investigate if the new technology can improve patient outcome and reduce complications after heart transplantation.
Read more 01 Dec 2020
Första patienten i den europeiska hjärtpreservationsstudien har blivit transplanterad
Den första patienten i XVIVOs europeiska hjärtpreservationsstudie transplanterades under november månad. Den patentskyddade hjärtpreservationsteknologin, vilken utvecklats av Professor Stig Steen och kommersialiseras av XVIVO, använder en ny teknik för bevarande av donatorhjärtat under transport. Nio europeiska transplantationscentran kommer att inkludera totalt 202 patienter i studien som ligger till grund för en ansökan om regulatoriskt godkännande i Europa. Studiens mål är att undersöka om den nya tekniken kan förbättra kliniska resultat och minska komplikationer efter hjärttransplantation.
Read more 20 Nov 2020
Publication in The Lancet shows better survival of transplanted kidneys after cold machine perfusion with oxygen
An article published in the scientific journal The Lancet today, shows that oxygenated perfusion of kidneys before transplantation has a significant impact on the first-year result after transplantation: less graft failure, better function and lower rejection of the kidney when compared to cold perfusion alone. The randomized trial, with kidneys aged 50 years or older, donated after circulatory death was done in 19 European transplant centers and included 212 patients. The Kidney Assist Transport device, used in the trial described in the Lancet article, is CE-marked and XVIVO intends to submit an application to the FDA during 2021 for the device.
Read more